Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Scoring System Stratifies Risk of Heart Failure in Patients With Acute Leukemia

May 18th 2020

Baseline clinical characteristics coupled with measurable cardiac parameters can be used to predict the risk of heart failure among adults with acute leukemia who receive anthracycline-based therapy, according to recent study findings.

Ruxolitinib Demonstrates Early Efficacy in Chronic GVHD

May 15th 2020

Rushang D. Patel, MD, PhD, discusses the potential role of ruxolitinib in the treatment of patients with cGVHD.

Dr. Kansagra on Updates With CAR T-Cell Therapy in Hematologic Cancers

May 15th 2020

Ankit Kansagra, MD, discusses key updates with CAR T-cell therapy in hematologic cancers.

CLR 131 Mechanism of Action

May 15th 2020

Ruxolitinib Demonstrates Early Efficacy in Chronic GVHD

May 15th 2020

Rushang D. Patel, MD, PhD, discusses the potential role of ruxolitinib in the treatment of patients with cGVHD.

Dr. Daver on Anticipated Breakthroughs in AML

May 15th 2020

Naval G. Daver, MD, discusses anticipated breakthroughs in acute myeloid leukemia (AML).

Brentuximab Vedotin Approved in Europe for Frontline ALCL

May 14th 2020

The European Commission has approved brentuximab vedotin for use in combination with chemotherapy for the frontline treatment of adult patients with systemic anaplastic large cell lymphoma.

SNDX-5613 Shows Early Promise in Acute Leukemias

May 14th 2020

Michael J. Thirman, MD, further discusses the novel compound, SNDX-5613, and sheds light on the next steps for this research.

Dr. Pagel on the Implications of Polatuzumab Vedotin Approval in DLBCL

May 14th 2020

John M. Pagel, MD, PhD, discusses the implications of the FDA approval of polatuzumab vedotin in diffuse large B-cell lymphoma.

Community Advice: SQ Formulation of Daratumumab

May 13th 2020

Real-World Experience With SQ Monoclonal Antibodies

May 13th 2020

Study Overview: COLUMBA and PLEIADES

May 13th 2020

Infusion-Related Adverse Events

May 13th 2020

Medication Supplements Prior to IV Administration

May 13th 2020

Intravenous Administration and Hepatitis

May 13th 2020

The Intravenous Administration of Monoclonal Antibodies

May 13th 2020

MRD in Acute Lymphoblastic Leukemia: Why, How, When, and Whom to Test?

May 13th 2020

During a recent OncLive Peer Exchange®, a panel of experts in adult and pediatric leukemias provided an update on minimal residual disease testing in acute lymphoblastic leukemia.

Dr. Patel on the Clinical Implications of Luspatercept Approval in MDS

May 13th 2020

Prapti Patel, MD, discusses the clinical implications of the FDA approval of luspatercept-aamt in myelodysplastic syndrome.

PET Scans and Novel Therapies Propel Progress in Hodgkin Lymphoma

May 13th 2020

Tatyana Feldman, MD, discusses the significance of PET-adapted strategies in Hodgkin lymphoma, novel therapies that have emerged in the pipeline, and where future research is headed.

Omidubicel Succeeds in Phase 3 Trial in High-Risk Hematologic Malignancies

May 12th 2020

Omidubicel met the primary end point of time to neutrophil engraftment in patients with high-risk hematologic malignancies undergoing a bone marrow transplant.